#52 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians need to understand this evidence linking adolescent cannabis use to substantially elevated psychotic disorder risk to provide informed counseling to young patients and families about potential neurodevelopmental harms. If federal rescheduling occurs, it may reduce perceived risk and increase adolescent access, making clinical conversations about cannabis even more critical for prevention of serious psychiatric outcomes. These data support psychiatrists and primary care physicians in discussing cannabis-specific risks during developmental periods when the brain remains vulnerable to psychotic illness.
A 2025 cohort study tracking 463,000 adolescents found that cannabis use was associated with more than double the risk of developing psychotic disorders, with particularly elevated risks during pregnancy and critical developmental windows. A Harvard neuroscientist presented these findings to federal court in the context of cannabis rescheduling deliberations, arguing that potential changes to the drug’s legal status should account for serious neuropsychiatric risks, especially in vulnerable populations. The evidence suggests that adolescent brain development and perinatal exposure represent critical periods of heightened susceptibility to cannabis-induced psychotic illness. These findings have direct clinical implications for counseling patients, particularly pregnant individuals and teenagers seeking cannabis for medical or recreational purposes, as they underscore the need for informed consent discussions about psychosis risk. Clinicians should integrate this neurobiological evidence into risk-benefit assessments and consider it when advising patients on cannabis use during key developmental periods.
“This 2025 cohort study of 463,000 adolescents reporting doubled psychotic disorder risk in cannabis users is significant and warrants serious attention from clinicians and families, though we’ll need to examine effect sizes, confounding variables, and whether this holds across diverse populations before making sweeping policy conclusions. What this does tell us clearly is that adolescent brains remain developmentally vulnerable, and the evidence supporting caution during this window continues to strengthen.”
🧠 While recent observational data linking adolescent cannabis use to psychotic disorders warrants clinical attention, healthcare providers should interpret these findings within their methodological context before substantially altering counseling practices. The doubled risk estimate from a large cohort study is notable but does not establish causation, and important confounders such as genetic predisposition, concurrent substance use, mental health comorbidities, and socioeconomic factors may partially explain the association. Additionally, the absolute incidence of psychosis in adolescent cannabis users remains relatively low, and applicability to individual patients varies considerably based on personal and family psychiatric history. Rather than adopting categorical messaging about cannabis and psychosis, clinicians can use this evidence to inform nuanced, developmentally appropriate conversations with adolescents and families about risks, particularly those with personal or family histories of psychotic illness. Ultimately, the rescheduling debate should not distract from the core clinical task: ass
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
